SciSparc (SPRC) Competitors $5.69 -0.30 (-5.01%) Closing price 08/5/2025 03:59 PM EasternExtended Trading$5.82 +0.13 (+2.20%) As of 08/5/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. CARM, NXTC, LPTX, BFRG, TXMD, ERNA, BIVI, MTVA, BCDA, and PHIOShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Carisma Therapeutics (CARM), NextCure (NXTC), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), TherapeuticsMD (TXMD), Ernexa Therapeutics (ERNA), BioVie (BIVI), MetaVia (MTVA), BioCardia (BCDA), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors Carisma Therapeutics NextCure Leap Therapeutics Bullfrog AI TherapeuticsMD Ernexa Therapeutics BioVie MetaVia BioCardia Phio Pharmaceuticals Carisma Therapeutics (NASDAQ:CARM) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Does the media favor CARM or SPRC? In the previous week, SciSparc had 4 more articles in the media than Carisma Therapeutics. MarketBeat recorded 5 mentions for SciSparc and 1 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 beat SciSparc's score of -0.01 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SciSparc 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, CARM or SPRC? SciSparc has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.66-$60.48M-$1.56-0.20SciSparc$1.31M2.30-$6.28MN/AN/A Do insiders and institutionals have more ownership in CARM or SPRC? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate CARM or SPRC? Carisma Therapeutics currently has a consensus target price of $1.93, indicating a potential upside of 520.97%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Carisma Therapeutics is more favorable than SciSparc.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71SciSparc 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CARM or SPRC more profitable? SciSparc has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% SciSparc N/A N/A N/A Which has more risk & volatility, CARM or SPRC? Carisma Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. SummaryCarisma Therapeutics beats SciSparc on 9 of the 14 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.20M$2.53B$5.59B$9.53BDividend YieldN/A1.77%4.73%4.14%P/E RatioN/A9.1628.9123.88Price / Sales2.30717.24445.5998.82Price / CashN/A159.4135.6858.35Price / Book0.315.078.165.60Net Income-$6.28M$31.61M$3.25B$265.26M7 Day Performance-9.39%-0.38%1.17%-0.14%1 Month Performance-16.63%5.79%8.27%6.08%1 Year Performance-26.57%3.58%29.19%24.22% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.3162 of 5 stars$5.69-5.0%N/A-20.4%$3.20M$1.31M0.004Short Interest ↑CARMCarisma Therapeutics2.3722 of 5 stars$0.34-7.2%$1.93+467.7%-65.2%$14.17M$19.96M-0.2220Upcoming EarningsGap DownNXTCNextCure4.3619 of 5 stars$5.24-5.4%$33.00+529.8%-71.3%$14.02MN/A-0.2590Upcoming EarningsGap DownLPTXLeap Therapeutics1.8956 of 5 stars$0.33-1.6%$3.38+910.5%-84.2%$13.84MN/A-0.2040Upcoming EarningsGap DownBFRGBullfrog AI0.7676 of 5 stars$1.45-2.7%N/A-43.5%$13.66M$60K-1.794TXMDTherapeuticsMD0.596 of 5 stars$1.16-0.9%N/A-34.9%$13.42M$1.76M0.00420Positive NewsUpcoming EarningsERNAErnexa Therapeutics0.8395 of 5 stars$1.79-6.3%N/A-93.2%$13.17M$580K-0.2210Upcoming EarningsBIVIBioVie0.1923 of 5 stars$6.97-1.8%N/A+68.8%$12.96MN/A-0.0910MTVAMetaVia1.4912 of 5 stars$0.63-4.4%$7.50+1,081.8%N/A$12.43MN/A0.008News CoverageGap DownBCDABioCardia3.0049 of 5 stars$2.22-3.1%$25.00+1,026.1%-32.2%$12.22M$3K-0.9540Upcoming EarningsGap DownPHIOPhio Pharmaceuticals2.5659 of 5 stars$2.54+0.4%$14.00+451.2%-15.2%$12.19MN/A-0.4010Gap Up Related Companies and Tools Related Companies CARM Alternatives NXTC Alternatives LPTX Alternatives BFRG Alternatives TXMD Alternatives ERNA Alternatives BIVI Alternatives MTVA Alternatives BCDA Alternatives PHIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
